ACT 15
Latest Information Update: 10 Jul 1998
At a glance
- Originator Chugai Pharmaceutical
- Developer Asahi Glass; Chugai Pharmaceutical
- Class Calcium regulators; Osteoporosis therapies
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 10 Jul 1998 Discontinued-Preclinical for Postmenopausal osteoporosis in Japan (Unknown route)
- 25 Sep 1996 New profile
- 25 Sep 1996 Preclinical development for Postmenopausal osteoporosis in Japan (Unknown route)